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Vasoactive neuropeptides (VNs) such as pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal
peptide (VIP) have critical roles as neurotransmitters, vasodilators including perfusion and hypoxia regulators, as well as immune
and nociception modulators. They have key roles in blood vessels in the central nervous system (CNS) including maintaining
functional integrity of the blood brain barrier (BBB) and blood spinal barrier (BSB). VNs are potent activators of adenylate
cyclase and thus also have a key role in cyclic AMP production aﬀecting regulatory T cell and other immune functions. Virchow-
Robin spaces (VRSs) are perivascular compartments surrounding small vessels within the CNS and contain VNs. Autoimmunity
of VNs or VN receptors may aﬀect BBB and VRS function and, therefore, may contribute to the aetiology of neurological-
related conditions including multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis. VN autoimmunity will likely
aﬀectCNSandimmunologicalhomeostasis.Variouspharmacologicalandimmunologicaltreatmentsincludingphosphodiesterase
inhibitors and plasmapheresis may be indicated.
Copyright © 2008 D. R. Staines et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Vasoactive neuropeptides (VNs) (e.g., pituitary adeny-
late cyclase-activating polypeptide (PACAP) and vasoactive
intestinal peptide (VIP)) are widely distributed in the
centralnervoussystem(CNS)andperipheralnervoussystem
(PNS) including autonomic nervous system (ANS) and
peripheral tissues including heart, lung, pancreas, adrenal
gland, gonads, and gastrointestinal tract as well as immune
cells and lymphatic system [1].
VNs have critical roles and functions as neurotrans-
mitters and neuroregulators, neurotrophic stimulators, hor-
monal regulators, vasodilators (including perfusion and
hypoxia regulators), as well as immune and nociception
modulators. They have key roles in blood vessel function in
the CNS and contribute to high-level neurological functions
including memory and learning [2]. They have a well-
described neuroprotective role [3] and act as inﬂammatory
mediators in microglial activation [4].
VNs exert potent eﬀects in metabolism as they have
a vital role in cyclic adenosine monophosphate (cAMP)
production and regulation through adenylate cyclase (AC)
activation.Immunologicaldysregulationofvitalbiochemical
and/or epigenetic mechanisms aﬀecting VNs resulting in
down-regulation of cAMP are possible pathways by which
disease entities become manifest. Their role along with other
neurotrophic factors [5] in maintaining cAMP levels [6]m a y
be of vital importance for the integrity of blood brain barrier
(BBB) and blood spinal barrier (BSB).
BBB and BSB have traditionally been regarded as the
main barriers between the brain and spinal cordparenchyma
and the intravascular compartment and are, therefore,2 Mediators of Inﬂammation
important in keeping immune cells and macromolecules
from interfering with brain and spinal neurological pro-
cesses. However, disruption of BBB and BSB is well known
in certain pathological states suggesting that they function
more as a “sieve” rather than an absolute barrier.
Virchow-Robin spaces (VRSs) are compartments sur-
rounding small vessels within the CNS which contain
interstitial ﬂuid and, while some functional contact with
subarachnoid spaces may occur for solute exchange, they
may not contain CSF as commonly thought [7]. VRSs
have important connections with lymphatic drainage of
the head and neck [8], having intricate pial relations and
providing a surface for activity of neuropeptides, hormones,
and cytokines. Pial cells may have a role in protecting the
brain from exogenous catecholamines [9], and VRS may
have a complex role in leukocyte recruitment across the BBB
[10].
VNs are known to have neuroprotective eﬀects through
hypoxia protection on passage through the BBB [11]v i aa
transport mechanism which enables the intact peptides to
enter the parenchymal space of the brain [12]. Additionally,
V N sh a v ep r o t e c t i v ee ﬀects on neurons and glial cells [13].
VNs may have a signiﬁcant role in blood BBB/BSB function
and likely assist in immune regulation of VRS in the brain
and spinal cord. The present paper asserts that in view of
the many vital roles of VNs in CNS neuroregulatory and
immunological function including BBB function, autoim-
munity to VNs or VN receptors will have signiﬁcant eﬀects
on homeostasis resulting in disease states.
2. VASOACTIVE NEUROPEPTIDES IN
IMMUNOLOGICAL CONTROL
VNs exert inﬂuence over inﬂammatory control mechanisms
including inﬂuencing Th1 to Th2 shift, and the suppression
of TNF alpha [14] has been established in cAMP participa-
tion in vascular dysfunction involving endothelial cells [15].
The VRS has been identiﬁed as a location for immunore-
active lymphocytes in penetration of neuronal parenchyma
[16]. Also, VIP has been identiﬁed in connection with
neuronal function and VRS suggesting that VIP may have
a regulatory function associated with vasodilatation [17].
We assert that important immunoregulation occurs in VRS
and that this may involve VN regulation. Many regulatory
functions are dependent on IL-10 and IL-4, these may be
compromised in VN failure. Moreover, leakiness in BBB and
BSB functions may encourage development or relapses in
neurologicalconditions,suchasmultiplesclerosis(MS)[18].
Regulatory T cells (Tregs) function to control autoreac-
tive T cells in the periphery [19]. Moreover, Treg function
is substantially inﬂuenced by VNs [20] and may also have
inﬂuence over Th17 direction [21]. Loss of Treg function
in VRS will, therefore, have signiﬁcant implications for
inﬂammatory control. Moreover, Th17 development occurs
under IL-6 and TGF beta inﬂuence [22], and this may
be a key switching point from a protective Treg to an
autoimmune Th17 phenotype. Certainly, Th1 and Th17
ratios are important in brain and spinal inﬂammation
regulation [23].
Interestingly, a number of seemingly unrelated disorders
may be implicated in this postulated pathology. For example,
Crohn’s disease (CD) and MS are inﬂammatory disorders
with known Th1-directed cytokines and loss of Foxp3 Treg
function [24, 25].
As VRS have important roles in controlling macrophage
and perivascular inﬁltrates in MS [26], their immunological
function in relation to VNs becomes of considerable interest.
Complement-ﬁxing myelinolytic antigens have been iden-
tiﬁed in the VRS in early MS [27], indicating the possible
involvement of VRS in immune activity.
3. POSTULATED VASOACTIVE NEUROPEPTIDE
AUTOIMMUNITY AND THE BLOOD BRAIN BARRIER
VN autoimmunity has been postulated as a contributing
cause for some fatigue-related conditions [28]. The present
paper explores the possible role VN immune dysregulation
may have on VRS function and CNS activity as this anatom-
ical pathway may have a signiﬁcant bearing on disease
aetiology.
Because VNs are widely distributed in the CNS, neu-
rovascular, and immune systems, they exert extraordinary
inﬂuence on neurological, vascular, and immunological
functions. Signiﬁcantly, VNs exert mostly anti-inﬂammatory
activities and loss of their function, for example, through
autoimmune compromise, could become manifest as un-
modulated activation of immune responses. Autoimmunity
directed at VN guanine protein-coupled receptors (GPCRs)
is currently unproven and loss-of-function autoimmunity
to GPCRs generally is not widely documented. However,
parallels exist with other conditions such as Sjogren’s syn-
drome which has T cell and/or B cell antibody targeting
of acetylcholine GPCRs [29]. The role of VNs in linking
the innate and acquired immune systems [30] suggests
that there would be signiﬁcant eﬀects on homeostasis if
compromised.
Pain, fatigue, and dysregulation of nociception may
be prominent features in these syndromes as a result of
VN compromise in the CNS. Pain and nociception are
mediated through spinal and cerebral pathways particularly
via spinothalamic, spinoreticular, and spinomesencephalic
structures. The periaqueductal grey (PAG) region surround-
ing the third ventricle and cerebral aqueduct is a key
area for regulation of noxious stimuli. This area has high-
density VN presence and may be a prominent target for VN
autoimmune compromise. Similarly, VRS have a critical role
in maintaining the interstitial ﬂuid immunological milieu
a n dm a yb eav u l n e r a b l ea r e af o rV Nc o m p r o m i s e .
It is likely that BBB, BSB, and VRS play an important role
in immunological maintenance and homeostasis within the
CNS. Macrophages in VRS express MHC class II antigens
and interact with lymphocytes from the blood in initiating
and promoting immune responses to foreign antigens in
the brain. Immunological activity within VRS may have a
role in a number of neurological conditions. Moreover, sites
deﬁcient in BBB include the subarachnoid space and pial
surface, and circumventricular organs may be more prone
to macromolecule penetration of CSF, and this may haveD. R. Staines et al. 3
implications regarding autoimmune dysfunction within the
CNS [31]. Collections of macrophages may occur in VRS
following trauma in a proinﬂammatory context [32]a n d
pathological dilatation of VRS may occur from a variety of
causes including ischaemia [33].
VRS distribution in anatomically speciﬁc locations
reﬂects the functional attributes of these locations. For
example, VRS in the nucleus tractus solitarius in the
dorsal medulla oblongata suggests they may have a role
in viscerosensory and autonomic functions [34]. Capillary
diversity within the subfornical organ (SFO) and area
postrema (AP) may function as low-resistance pathways for
the rapid dispersion of blood-borne hormones inside their
organ boundaries and this may have a role in the regulation
of blood pressure and body ﬂuids [35]. Hence, these
functions linked to VRS microanatomy may be particularly
susceptible to VN compromise.
4. POSTULATED CEREBROVASCULAR AND
CNS EFFECTS OF VN FAILURE
Vascular compromise within the CNS possibly as a result of
VNcompromisemaygiverisetofeaturesconsistentwithcer-
tain forms of dementia. Fronto-temporal dementia (FTD) is
a neurodegenerative disease in which a vascular component
is suggested and immunoreactivity of Bax, a proapoptotic
protein regulated in part by VNs in astrocytes, suggests a role
for autoimmunity in the pathology of FTD [36]. Astrogliosis
in FTD corresponds with SPECT hypoperfusion, suggesting
that astrocyte disruption may be related to disturbances of
c e r e b r a lp e r f u s i o ni nF T D[ 37]. Cognitive dysfunction is
associatedwithreducedcerebralbloodﬂowindiﬀerenttypes
of dementia [38]. Moreover, VRS dilatation associated with
microvessel abnormality may contribute to the diagnosis of
vascular dementias [39]. Changes in social behaviour occur
in cerebrovascular comprise and may result from an FTD-
like syndrome [40]. Similarly, reduction in cortical blood
ﬂow has been identiﬁed in CFS patients [41, 42]; however,
these ﬁndings were not replicated in a study of twins with
CFS [43].
Astroglial water channel aquaporin (AQP4) is essen-
tial for the maintenance of blood-brain barrier integrity
[44]. Antibodies to AQP4 have a highly speciﬁc role in
neuromyelitis optica (NMO) and characteristically bind to
cerebral microvessels, pia mater, and VRSs [45]. Secretin is
important for other aquaporin expression via vasopressin.
Secretin receptor-null mice, for example, have reduced renal
expression of AQP2 and AQP4 [46]. Interestingly, VIP,
which is related to secretin, also has a relationship with
aquaporin distribution and function. An association with
VRS has been identiﬁed supporting the view that cortical
nerve cells release VIP in the perivascular space during
periods of activityand thuscontributetolocalvasodilatation
associated with neuronal function. There is an important
relationship whereby ATP over expression has a down-
regulatory impact on AQP4 expression [47]. Adenylate
cyclase compromise could have an impact on ATP levels
by failure to convert to cAMP, arguably maintaining high
levels of ATP with adverse consequences for AQP4 function.
Thus, VN failure may present with dementia-like signs and
symptoms.
5. CONCLUSIONS
Neurological conditions often present with fatigue and
other symptoms including memory and concentration loss,
emotional lability, and confusion. Multisystem involvement
including cerebrospinal eﬀects of these conditions may be
explained in part through VN compromise. In particular,
cerebrovascular and spinovascular compromise acting at
the ultra-microscopic level involving BBB and BSB may
contribute to these disorders. Compromise of VN receptors
critical to BBB and BSB functioning may have a role in these
disorders and should be the subject of further research.
ThispaperassertsthatCNSvascularcompromiseinclud-
ing immunological dysfunction of the VRS may be linked
to postulated VN autoimmunity. Evidence for compromise
of VN receptors at diﬀerent levels including VN recep-
tor mRNA, protein transcription, cellular migration and
traﬃcking, cell membrane localisation, as well as possible
antibody or T cell targeting will be required to support this
hypothesis.
There are signiﬁcant treatment implications from this
hypothesis.VNs,suchasPACAPandVIP,exertpotenteﬀects
in metabolism as they have a vital role in cAMP production
and regulation through AC activation. Phosphodiesterase
(PDE) enzymes metabolise cAMP as a means of feedback
regulation of cAMP levels. VN compromise will result in
impaired AC activation and hence impaired cAMP pro-
duction. Thus, phosphodiesterase inhibitors (PDEIs), novel
therapeutic substances used to promote cAMP levels, may
have a role in treatment of VN autoimmune conditions.
Proof of this hypothesis will require demonstration of
pathological antibodies or T cells speciﬁc to VN immuno-
logical pathology. Alternatively, antagonistic variants of VNs
themselves may exist.
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